Panagiotis Konstantinopoulos
Panagiotis Konstantinopoulos
Dana-Farber Cancer Institute, Harvard Medical School
Verified email at
Cited by
Cited by
Replication fork stability confers chemoresistance in BRCA-deficient cells
A Ray Chaudhuri, E Callen, X Ding, E Gogola, AA Duarte, JE Lee, ...
Nature 535 (7612), 382-387, 2016
Homologous-recombination-deficient tumours are dependent on Polθ-mediated repair
R Ceccaldi, JC Liu, R Amunugama, I Hajdu, B Primack, MIR Petalcorin, ...
Nature 518 (7538), 258-262, 2015
Homologous recombination deficiency: exploiting the fundamental vulnerability of ovarian cancer
PA Konstantinopoulos, R Ceccaldi, GI Shapiro, AD D'Andrea
Cancer discovery 5 (11), 1137-1154, 2015
Post-translational modifications and regulation of the RAS superfamily of GTPases as anticancer targets
PA Konstantinopoulos, MV Karamouzis, AG Papavassiliou
Nature reviews Drug discovery 6 (7), 541-555, 2007
Gene expression profile of BRCAness that correlates with responsiveness to chemotherapy and with outcome in patients with epithelial ovarian cancer
PA Konstantinopoulos, D Spentzos, BY Karlan, T Taniguchi, E Fountzilas, ...
Journal of clinical oncology 28 (22), 3555, 2010
Association and prognostic significance of BRCA1/2-mutation status with neoantigen load, number of tumor-infiltrating lymphocytes and expression of PD-1/PD-L1 in high grade …
KC Strickland, BE Howitt, SA Shukla, S Rodig, LL Ritterhouse, JF Liu, ...
Oncotarget 7 (12), 13587, 2016
Association of polymerase e–mutated and microsatellite-instable endometrial cancers with neoantigen load, number of tumor-infiltrating lymphocytes, and expression of PD-1 and PD-L1
BE Howitt, SA Shukla, LM Sholl, LL Ritterhouse, JC Watkins, S Rodig, ...
JAMA oncology 1 (9), 1319-1323, 2015
DNA Damage and Repair Biomarkers of Immunotherapy ResponseDNA Repair Biomarkers of Immunotherapy Response
KW Mouw, MS Goldberg, PA Konstantinopoulos, AD D'Andrea
Cancer discovery 7 (7), 675-693, 2017
Oestrogen receptor beta (ERβ) is abundantly expressed in normal colonic mucosa, but declines in colon adenocarcinoma paralleling the tumour's dedifferentiation
PA Konstantinopoulos, A Kominea, G Vandoros, GP Sykiotis, ...
European journal of cancer 39 (9), 1251-1258, 2003
Keap1 Mutations and Nrf2 Pathway Activation in Epithelial Ovarian CancerKeap1/Nrf2 Pathway in Epithelial Ovarian Cancer
PA Konstantinopoulos, D Spentzos, E Fountzilas, N Francoeur, ...
Cancer research 71 (15), 5081-5089, 2011
PARP inhibition elicits STING-dependent antitumor immunity in Brca1-deficient ovarian cancer
L Ding, HJ Kim, Q Wang, M Kearns, T Jiang, CE Ohlson, BB Li, S Xie, ...
Cell reports 25 (11), 2972-2980. e5, 2018
Single-arm phases 1 and 2 trial of niraparib in combination with pembrolizumab in patients with recurrent platinum-resistant ovarian carcinoma
PA Konstantinopoulos, S Waggoner, GA Vidal, M Mita, JW Moroney, ...
JAMA oncology 5 (8), 1141-1149, 2019
Cancer of the cervix, vagina, and vulva
PJ Eifel, AH Klopp, JS Berek, PA Konstantinopoulos
DeVita, Hellman, and Rosenberg's Cancer: Principles & Practice of Oncology …, 2018
EZH2 promotes degradation of stalled replication forks by recruiting MUS81 through histone H3 trimethylation
B Rondinelli, E Gogola, H Yücel, AA Duarte, M van de Ven, ...
Nature cell biology 19 (11), 1371-1378, 2017
Prediction of DNA Repair Inhibitor Response in Short-Term Patient-Derived Ovarian Cancer OrganoidsDNA Repair Profiling of HGSC Organoids
SJ Hill, B Decker, EA Roberts, NS Horowitz, MG Muto, MJ Worley, ...
Cancer discovery 8 (11), 1404-1421, 2018
PRECEDENT: a randomized phase II trial comparing vintafolide (EC145) and pegylated liposomal doxorubicin (PLD) in combination versus PLD alone in patients with platinum …
RW Naumann, RL Coleman, RA Burger, EA Sausville, E Kutarska, ...
J Clin Oncol 31 (35), 4400-4406, 2013
Management of AIDS-related Kaposi's sarcoma
G Di Lorenzo, PA Konstantinopoulos, L Pantanowitz, R Di Trolio, ...
The lancet oncology 8 (2), 167-176, 2007
PARP inhibitors in ovarian cancer: current status and future promise
JF Liu, PA Konstantinopoulos, UA Matulonis
Gynecologic oncology 133 (2), 362-369, 2014
Expression of the 27-kDa heat shock protein (HSP27) in gastric carcinomas and adjacent normal, metaplastic, and dysplastic gastric mucosa, and its prognostic significance
N Kapranos, A Kominea, P Konstantinopoulos, S Savva, S Artelaris, ...
Journal of cancer research and clinical oncology 128 (8), 426-432, 2002
Targeting MET as a strategy to overcome crosstalk-related resistance to EGFR inhibitors
MV Karamouzis, PA Konstantinopoulos, AG Papavassiliou
The lancet oncology 10 (7), 709-717, 2009
The system can't perform the operation now. Try again later.
Articles 1–20